Theorem Clinical Research

Drug Sponsors

Johnson & Johnson to accelerate Ebola vaccine program in collaboration with NIH

Thursday, September 4, 2014 12:29 PM

Johnson & Johnson has committed to accelerate its Ebola vaccine program in collaboration with the NIH. J&J will fast-track the development of a promising new combination vaccine regimen against Ebola and broadly collaborate to deliver immediate relief aid to address the current Ebola outbreak.

More... »


HHS contracts with Mapp Biopharmaceutical to develop ZMapp for Ebola

Thursday, September 4, 2014 12:22 PM

The development of a medication to treat illness from Ebola will be accelerated under a contract with the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).

More... »


Exelixis cuts 70% of employees following failed pivotal trial

Wednesday, September 3, 2014 12:41 PM

Exelixis, a California-based biopharmaceutical company developing small molecule therapies for cancer, has announced top-line results from the final analysis of COMET-1, the phase III pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed after treatment with docetaxel as well as abiraterone and/or enzalutamide. The trial did not meet its primary endpoint of demonstrating a statistically significant increase in overall survival (OS) for patients treated with cabozantinib as compared to prednisone.

More... »

Orgentec Diagnostika to acquire Corgenix

Friday, August 29, 2014 10:32 AM

Corgenix Medical, a Colorado-based, worldwide developer and marketer of diagnostic test kits, has agreed to be acquired by Orgentec Diagnostika, a specialty diagnostics company headquartered in Mainz, Germany. The strategic acquisition will extend both companies’ global distribution networks and broaden their portfoliod of specialty diagnostic assays.

More... »

Report: Pharma crosses new frontiers with global tiered pricing strategies

Wednesday, August 27, 2014 01:15 PM

Despite the adoption of tiered pricing strategies by pharmaceutical companies around the world, there is only a tenuous correlation between the prices of pharmaceutical products and the local economic conditions of the countries where they are launched, according to a comprehensive new study by IHS, a global source of critical information and insight, headquartered in Englewood, Colo.

More... »

Cilag International acquires Covagen

Wednesday, August 27, 2014 01:13 PM

Cilag International, a Switzerland-based affiliate of Janssen Pharmaceutical, a division of Johnson & Johnson, has acquired Covagen, a privately held biopharmaceutical company specializing in the development of multi-specific protein therapeutics through the FynomAb technology platform.

More... »

Medtronic acquires Sapiens Steering Brain Stimulation

Wednesday, August 27, 2014 01:12 PM

Medtronic, a Minneapolis, Minn., medical technology provider, has acquired Sapiens Steering Brain Stimulation (Sapiens SBS), a Netherlands-based, privately held developer of deep brain stimulation (DBS) technologies, for approximately $200 million in cash.

More... »

Covidien acquires Reverse Medical

Monday, August 25, 2014 02:11 PM

Covidien, a Dublin, Ireland-based global healthcare products company and manufacturer of medical devices and supplies, has acquired California-based Reverse Medical, a privately held medical device company focused on expanding the management of vascular disease. Financial terms of the transaction have not been disclosed.

More... »

Roche to acquire InterMune for $8.3 billion

Monday, August 25, 2014 02:02 PM

Roche and InterMune have entered into a definitive merger agreement under which Roche will fully acquire InterMune for $74 per share in cash, for a total transaction value of $8.3 billion on a fully diluted basis.

More... »

Pfizer, Gamida Cell ink investment and option agreement

Wednesday, August 20, 2014 01:31 PM

Gamida Cell, an Israel-based provider of stem cell expansion technologies and therapeutic products, has signed an investment and option agreement with Novartis Pharma. Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord, anticipated to be met during 2015.

More... »

Subscribe to The CenterWatch Monthly
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs